Journal of Immunology Research / 2016 / Article / Tab 3

Research Article

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy

Table 3

Evaluation of the potential impact of ADA on efficacy among patients with treatment-emergent ADA.

TreatmentPatientADA + time pointDSN (days)ANC AUCANC maximumANC nadir

Phase II study

Pegfilgrastim10D85Cycle 10160.259.606.8
Cycle 20212.9514.907.9
Cycle 30116.258.503.6
Cycle 4091.857.502.4

Lipegfilgrastim2D360Cycle 11154.2420.390.18
Cycle 21170.2021.400.0
Cycle 30225.4027.641.25
Cycle 40202.2628.421.72
1D85Cycle 10127.8017.000.8
Cycle 20147.259.602.2
Cycle 30121.608.300.7
Cycle 40179.5516.701.3

Phase III study

Pegfilgrastim17D85Cycle 10219.8847.990.89
Cycle 20198.1513.732.2
Cycle 30302.9868.322.16
Cycle 40315.6357.424.06

Lipegfilgrastim13D360Cycle 12160.1626.140.25
Cycle 20257.9551.921.25
Cycle 30300.2458.911.2
Cycle 40291.3668.751.45

ADA: antidrug antibody; ANC: absolute neutrophil count; AUC: area under the curve; D85: day 85; D360: day 360; DSN: duration of severe neutropenia.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.